Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 2,904 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Capsules Clear all
Recruiting Phase 3 Interventional

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT07179380
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease
Interventions
Treprostinil Palmitil Inhalation Powder, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
19
States / cities
Phoenix, Arizona • Fresno, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 30, 2026, 1:47 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

NCT05145413
View directory record Official record
Conditions
Schizophrenia
Interventions
Xanomeline and Trospium Chloride Capsules, Placebo
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 65 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
79
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 61 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 30, 2026, 1:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First in Human Trial Evaluating THB335 in Healthy Participants

NCT06425861
View directory record Official record
Conditions
Healthy
Interventions
THB335 single dose, Single dose placebo, THB335 fasted/fed, Placebo fasted/fed, THB335 multiple dose, Multiple dose placebo
Drug
Lead sponsor
Third Harmonic Bio, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 30, 2026, 1:47 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy

NCT05266586
View directory record Official record
Conditions
Dyslipidemias, High Cholesterol, Hypercholesterolemia
Interventions
Obicetrapib, Ezetimibe 10mg, Obicetrapib placebo, Ezetimibe placebo
Drug · Other
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
16
States / cities
Los Angeles, California • Northridge, California • Ocala, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 30, 2026, 1:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers

NCT01404754
View directory record Official record
Conditions
Psychological Effects of Study Drug
Interventions
Lactose (inactive placebo), midomafetamine HCl
Drug
Lead sponsor
Resilient Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2022
U.S. locations
3
States / cities
Boulder, Colorado • Santa Fe, New Mexico • Mt. Pleasant, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 30, 2026, 1:47 AM EDT
Completed Phase 2 Interventional Results available

A Controlled Trial to Evaluate the Effects of GanedenBC30 on the Immune System

NCT01184456
View directory record Official record
Conditions
HIV Infection, Gastrointestinal Symptoms
Interventions
GanedenBC30, GBI-30, PTA-6086, Placebo
Dietary Supplement · Drug
Lead sponsor
AIDS Healthcare Foundation
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Oct 30, 2026, 1:47 AM EDT
Completed Phase 1Phase 2 Interventional Results available

NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Occipital Horn Syndrome

NCT04977388
View directory record Official record
Conditions
Menkes Disease, Occipital Horn Syndrome
Interventions
Droxidopa, Placebo
Drug · Other
Lead sponsor
Stephen G. Kaler, MD
Other
Eligibility
18 Years to 50 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 30, 2026, 1:47 AM EDT
Completed Not applicable Interventional

Feeding Trial to Determine How Combinations of Different Dietary Bioactive Ingredients Influence High Density Lipoprotein (HDL) Metabolism

NCT01803594
View directory record Official record
Conditions
Dyslipidemia
Interventions
Krill Oil, Lutein, Nicotinic acid, Dairy phospholipids, Control
Dietary Supplement · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2022 · Synced Oct 30, 2026, 1:47 AM EDT
Terminated Phase 2 Interventional Results available

AGN-242428 in the Treatment of Plaque Psoriasis

NCT03339999
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
AGN-242428, Placebo
Drug
Lead sponsor
Vitae Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
15
States / cities
Birmingham, Alabama • Tucson, Arizona • Fort Smith, Arkansas + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 30, 2026, 1:47 AM EDT
Completed Phase 2 Interventional Results available

Asacol Acute Diverticulitis(DIVA)Study

NCT00554099
View directory record Official record
Conditions
Diverticulitis
Interventions
Mesalamine, Probiotic, Placebo, Dietary Advice, Antibiotic for Diverticulitis
Drug · Other
Lead sponsor
Warner Chilcott
Industry
Eligibility
35 Years to 85 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
36
States / cities
Tucson, Arizona • Los Angeles, California • Merced, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 30, 2026, 1:47 AM EDT
Recruiting Phase 4 Interventional

Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis

NCT07614321
View directory record Official record
Conditions
Multiple Sclerosis, Lower Urinary Track Symptoms
Interventions
Silodosin 8 mg, Placebo
Drug
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 30, 2026, 1:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of VBY-891 in Healthy Volunteers After Single or Multiple (7 Days) of Oral Dosing (VBY891P1)

NCT01947738
View directory record Official record
Conditions
Healthy
Interventions
VBY-891, Placebo
Drug
Lead sponsor
Virobay Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 31, 2013 · Synced Oct 30, 2026, 1:47 AM EDT
Terminated Phase 3 Interventional

Study of EG-1962 Compared to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage

NCT02790632
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Aneurysmal
Interventions
EG-1962 (nimodipine microparticles), Enteral Nimodipine
Drug
Lead sponsor
Edge Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 30, 2026, 1:47 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

How DHEA Supplements Affect Coagulation in Women Using Birth Control Pills

NCT03418363
View directory record Official record
Conditions
Contraceptive Usage, Coagulation
Interventions
DHEA Oral Capsule, Placebo Oral Capsule
Dietary Supplement · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 23, 2020 · Synced Oct 30, 2026, 1:47 AM EDT
Completed Phase 3 Interventional Results available

B. Lactis HN019 for Functional Constipation

NCT01463293
View directory record Official record
Conditions
Constipation
Interventions
B. lactis HN019, Placebo
Dietary Supplement
Lead sponsor
Fonterra Research Centre
Industry
Eligibility
18 Years to 70 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
12
States / cities
Glendale, Arizona • Encinitas, California • Garden Grove, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 30, 2026, 1:47 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder

NCT07193563
View directory record Official record
Conditions
Social Anxiety Disorder (SAD)
Interventions
ENX-102, Placebo
Drug · Other
Lead sponsor
Engrail Therapeutics INC
Industry
Eligibility
18 Years to 70 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
20
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 30, 2026, 1:47 AM EDT
Completed Phase 2 Interventional Results available

Effect of KYG0395 on Primary Dysmenorrhea

NCT01588236
View directory record Official record
Conditions
Primary Dysmenorrhea
Interventions
high dose KYG0395, lower dose KYG0395, Placebo
Drug
Lead sponsor
Jiangsu Kanion Pharmaceutical Co., Ltd
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
23
States / cities
Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 30, 2026, 1:47 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Reduction of Postoperative Gastrointestinal Dysmotility Following Total Laparoscopic Hysterectomy.

NCT03800745
View directory record Official record
Conditions
Postoperative Passage of Flatus, Postoperative Bowel Movement
Interventions
Colace 100Mg Capsule, Miralax
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Jun 2, 2020 · Synced Oct 30, 2026, 1:47 AM EDT
Completed Phase 1 Interventional

A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive Disorder

NCT03374475
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
JNJ-42847922 20mg, JNJ-42847922 40mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
San Diego, California • San Marcos, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 30, 2026, 1:47 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)

NCT01259492
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Placebo, Ritalin LA 20 mg, Ritalin LA 30 mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
725 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
21
States / cities
Little Rock, Arkansas • Beverly Hills, California • Spring Valley, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Oct 30, 2026, 1:47 AM EDT
Completed Phase 2 Interventional Results available

Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation

NCT04110145
View directory record Official record
Conditions
Functional Constipation
Interventions
Linaclotide, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
2 Years to 5 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
18
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Oct 30, 2026, 1:47 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Observational Metabolic Health Study

NCT06790407
View directory record Official record
Conditions
Healthy
Interventions
Mimio Study Product, Placebo
Dietary Supplement
Lead sponsor
Mimio Health, Inc.
Industry
Eligibility
55 Years and older
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Oct 30, 2026, 1:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Moringa Supplementation for Improved Milk Output

NCT05333939
View directory record Official record
Conditions
Breastfeeding
Interventions
Moringa leaf powder, Placebo
Dietary Supplement · Other
Lead sponsor
University of Kentucky
Other
Eligibility
0 Months and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 30, 2026, 1:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone: Sub-Study I

NCT02811939
View directory record Official record
Conditions
Healthy
Interventions
Active Dronabinol, Active Pregnenolone, Placebo Dronabinol, Placebo Pregnenolone
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 30, 2026, 1:47 AM EDT